Carmel Diagnostics

Carmel Diagnostics has developed a method for measuring the oxidative stress (OS) of biological liquids, a recognized biomarker of health and disease and a key diagnostics parameter. This OS parameter is measured using thermochemiluminescence (TCL) technology. The company's lead product is focused on the process of embryo selection in in-vitro fertilization (IVF). The Fertissimo TCL Analyzer is a noninvasive embryo selection system for the IVF market, offering up to a 20% increase in successful IVF pregnancies. Effective embryo viability assessment significantly improves the success rate and reduces the risk of multiple births. Carmel Diagnostics has performed two successful proof-of-concept studies covered by peer-reviewed articles on the applications of risk stratification for patients with congestive heart failure and embryo selection in the IVF process, and is currently performing a clinical validation study for the IVF application. Carmel Diagnostics was awarded a Horizon 2020 phase-2 grant.

Carmel Diagnostics has raised $6.94M in total funding across 5 rounds. The company is currently at the Seed stage. Key investors include Undisclosed Investor(s).

Carmel Diagnostics was founded in 2009 by Cnaani Tzali (Founder & CEO), Sergei Shnizer (Co-founder & CTO).

Carmel Diagnostics operates in Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, Medical Devices, Diagnostics Devices. Target customers: Healthcare & Life Sciences, Healthcare, Laboratories, Consumers, Demographics & Family, Women.

Carmel Diagnostics is based in Khayim Barlev St 9, Kiryat Tiv'on, Israel, North District.